Kidney patients have a higher risk of severe COVID-19 infection - vaccinations reduced the need for hospitalization
24.9.2025 11:42:36 EEST | HUS | Press release
A recent study shows that COVID-19 vaccinations reduced morbidity and mortality due to COVID-19 in dialysis and kidney transplant patients compared to unvaccinated patients. Patients who had been vaccinated were at half the risk of becoming hospitalized because of COVID-19 compared to unvaccinated patients. The risk of death decreased significantly with booster vaccines especially in kidney transplant patients. However, the vaccine protection of these patients remained weaker than that of healthy people.

A study led by Professor Patrik Finne and the doctoral dissertation of Bachelor of Medicine Hanna Helanne focused on patients (5,755) in the Finnish Registry for Renal Diseases who were on dialysis or had a kidney transplant. These patients are at greater risk of developing a severe form of COVID-19 compared to healthy people.
The study assessed how the COVID-19 vaccine would prevent hospitalization and mortality in patients receiving renal replacement therapy compared to unvaccinated persons.
Each research subject had 10 control persons of the same age, sex and municipality of residence. During the years of the study 2020–2022, 1,713 kidney patients and 10,702 control persons contracted an infection caused by COVID-19.
Infections in kidney patients more severe and vaccine effectiveness lower
COVID-19 vaccinations significantly reduced the risk of kidney patients becoming hospitalized, but not as effectively as in control persons. More than three booster vaccines reduced the mortality rate of kidney transplant patients by 62% compared to unvaccinated patients.
In patients receiving dialysis treatment, 2–3 vaccine doses reduced the risk of hospitalization by 47 per cent and in kidney transplant patients by 50 per cent. In control persons, COVID-19 vaccines prevented three out of four hospitalizations.
The COVID-19 infections of dialysis patients were more severe than those of the control persons and their vaccine efficacy was lower. However, the vaccines prevented the hospitalization of every other patient. Booster vaccines reduced the risk of death significantly especially in kidney transplant patients.
Kidney patients are in the target group of the autumn booster vaccine.
Keywords
Contacts
Patrik FinneProfessor, HUS Abdominal Center
Tel:+358 50 427 0800patrik.finne@hus.fiHanna HelanneDoctoral Researcher, Bachelor of Medicine, University of Helsinki
hanna.helanne@helsinki.fiAbout HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Genetiska undersökningar kan avslöja orsaken till plötslig oförklarlig död hos unga14.9.2026 09:18:15 EEST | Pressmeddelande
Den bakomliggande orsaken till plötslig oförklarlig död hos unga kan vara en sällsynt ärftlig sjukdom som nödvändigtvis inte kommer fram i vanliga undersökningar. Genetiska undersökningar är en viktig del särskilt i utredningen av plötsliga oväntade dödsfall hos unga. Genetiska undersökningar kan också bidra till att identifiera släktingar som omfattas av risken och förebygga eventuella allvarliga hjärthändelser.
Geenitutkimus voi paljastaa syyn nuoren selittämättömälle äkkikuolemalle14.9.2026 09:18:15 EEST | Tiedote
Nuoren selittämättömän äkkikuoleman taustalla voi olla harvinainen perinnöllinen sairaus, joka ei välttämättä tule esiin tavanomaisissa tutkimuksissa. Geenitutkimus on tärkeä osa erityisesti nuorten odottamattomien äkkikuolemien syyn selvittämisessä. Geenitutkimus voi myös auttaa tunnistamaan riskissä olevia sukulaisia ja ehkäistä mahdollisia vakavia sydäntapahtumia.
Genetic testing may reveal the cause of sudden death in a young person14.9.2026 09:18:15 EEST | Press release
The reason for an unexplained sudden death of a young person may be a rare hereditary disease that can remain undetected in standard examinations. Genetic testing is an important part of investigating the cause of an unexpected sudden death, especially in adolescents. Genetic testing may also help to identify relatives who are at risk of sudden death, and to prevent possible severe cardiac events.
Svår RS-virusinfektion kan öka risken att barnet drabbas av astma i den tidiga barndomen8.9.2026 07:55:55 EEST | Pressmeddelande
En svår RS-virusinfektion i spädbarnsåldern ser ut att öka risken för pipande andning och astma i den tidiga barndomen. I en nyligen publicerad studie identifierades också ett nytt genområde som är förknippat med benägenheten att drabbas av RS-virusinfektion.
Vaikea RSV-infektio voi lisätä lapsen riskiä sairastua astmaan varhaislapsuudessa8.9.2026 07:55:55 EEST | Tiedote
Vauvana sairastettu vakava RSV-infektio näyttää lisäävän hengityksen vinkunan ja astman riskiä varhaislapsuudessa. Vastajulkaistussa tutkimuksessa tunnistettiin myös uusi geenialue, joka liittyy alttiuteen sairastua RSV-infektioon.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom